STAT+: Pharmalittle: We’re reading about another AstraZeneca trial failure, a Novo name change, and more

STAT PlusNewsletterPharmalot Pharmalittle: We’re reading about another AstraZeneca trial failure, a Novo name change, and more Scholar Rock won approval for the first therapy to target muscle loss in spinal muscle atrophy Manage alerts for this article Email this article Share this article By Ed SilvermanSept. 14, 2026 Pharmalot Columnist, Senior Writer Ed Silverman[email protected]Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating. Now, though, that oh-too-familiar routine of meetings, deadlines, and the like has returned with a vengeance.

You knew this would happen, yes? To cope, we are relying, as always, on a cuppa stimulation. Our choice today is blueberry hibiscus.

Feel free to join us. Remember, no prescription or prior authorization is required. Meanwhile, here are a few items of interest.

Best of luck accomplishing your goals, and we hope you conquer the world. And, of course, do keep in touch. … AstraZeneca disclosed that a breast cancer pill failed in a pivotal trial testing it as a first-line therapy in advanced tumors, a result that could limit the use of the medicine, STAT notes.

The drug, camizestrant, in combination with another medicine did not outperform standard treatment on a measure of how long patients went before their cancer progressed. The drug earlier this month won accelerated approval in the U.S. as a treatment for patients who develop a mutation in their tumors that’s a sign of emerging drug resistance.

Had the trial been successful, it could have opened up a much larger market for the drug. Advertisement Scholar Rock received U.S. Food and Drug Administration approval for the first-ever therapy that targets the loss of muscle in spinal muscle atrophy, raising hopes that patients with the rare neurological disorder might have a better chance of moving and walking independently, STAT writes.

The FDA approved the drug, Isembyld, for use in adults and children 2 years and older who are currently receiving SMA therapies that target SMN2, a key gene for neurons that control movement. The approval marks another step forward for patients with spinal muscular atrophy, a rare and progressive disease that destroys nerve cells that control speaking, breathing, and walking. Babies who go untreated usually die by the age of 2.

STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account?

Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+.

Subscribe Log In pharmalittle, STAT+ Submit a correction requestReprints Ed Silverman Pharmalot Columnist, Senior Writer Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Newsletter Understand how science, health policy, and medicine shape the world every day Recommended Pharmalot September 13, 2026 STAT Plus: Trump’s secretive pharma deals may undermine ‘most-favored nation’ pricing, an analysis suggests Pharmalot September 11, 2026 STAT Plus: Pharma wins a battle over the cost of wastewater treatment in Europe Advertisement Pharmalot September 11, 2026 STAT Plus: Up and down the ladder: The latest comings and goings Pharmalot September 11, 2026 STAT Plus: Pharmalittle: We’re reading about anxious Novartis investors, patent expirations for biologics, and more Pharmalot September 10, 2026 STAT Plus: The gifts from pharma companies that keep on giving Subscriber Picks